Congratulations to Shelby Fertal on the publication of her review article on the stromal impacts on new therapies for TNBC patients!

In this collaborative review with Drs. Kari Wisinski and Johanna Poterala, we summarize the recent outcomes from clinical trials with new agents for metastatic triple-negative breast cancer, specifically focusing on immunotherapies targeting the PD-1/PD-L1 pathway and antibody–drug conjugates. In addition to the clinical data supporting these therapies, we review the impact of the tumor microenvironment on the effectiveness of these therapies.

Read the full article at: